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Summary
Objective: As our population ages, treatment for joint pain associated with articular cartilage damage is becoming a prevalent challenge.
Accordingly, this work investigates local delivery of two regulatory proteins e transforming growth factor-b1 (TGF-b1) and insulin-like growth
factor-1 (IGF-1) e to cartilage defects from degradable scaffolds as a potential strategy for improving cartilage repair.
Method: The effects of TGF-b1 and/or IGF-1 delivery on osteochondral repair in adult rabbits were examined through histomorphometric anal-
ysis of 11 markers of osteochondral repair.
Results: Complete scaffold degradation occurred allowing for assessment of the healing response at 12 weeks post-surgery. When compared
to untreated defects, higher scores were observed with IGF-1-treated defects for the six markers of neo-surface repair: neo-surface morphol-
ogy, cartilage thickness, surface regularity, chondrocyte clustering, and the chondrocyte/glycosaminoglycan content of the neo-surface and
the cartilage surrounding the defect. Surprisingly, the beneﬁts of IGF-1 delivery were not maintained when this growth factor (GF) was co-de-
livered with TGF-b1, despite numerous in vitro reports of the combinatory actions of these GFs.
Conclusions: While localized delivery of IGF-1 may be a promising repair strategy, further in vivo assessment is necessary, since ﬁbrous tis-
sue was commonly observed in the neo-surface of all treatment groups. More importantly, this study highlights the need to rigorously examine
GF interactions in the wound healing environment and demonstrates that in vitro observations do not directly translate to the in vivo setting.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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The prevalence of joint pain among adults is projected to
steadily increase throughout the next 25 years. In fact, by
2030, an estimated 65 million adult Americans will be diag-
nosed with arthritis1. Accordingly, clinicians, biologists, and
biomedical engineers are working to develop new cartilage
repair strategies by investigating how various bioactive fac-
tors participate in the regulation of healthy articular cartilage
(AC)2,3. Numerous signaling molecules have been isolated
from AC2. However, research efforts to understand how
multiple factors interact have primarily been limited to
in vitro studies4e12. Given the inherent difﬁculties associated
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Received 19 December 2005; revision accepted 23 July 2006.1with maintaining in vitro cultured chondrocytes in their differ-
entiated state13, in vivo methods for studying growth factor
(GF) interactions in the wound healing environment are
necessary.
While a few carriers have been developed for dual GF
delivery to calciﬁed and vascular tissues14e16, cartilage re-
search has yet to employ synthetic carriers for controlled
dual drug delivery in vivo. Fibrin clots have been utilized
for GF localization in chondral defects17, but in order to
investigate how the kinetics of release affect healing, syn-
thetic carriers which allow for precise tailoring of drug re-
lease rates and material properties are desired. Toward
this goal, our laboratory has developed a novel class of
hydrogels to deliver multiple GFs18,19. These systems are
based on oligo(poly(ethylene glycol) fumarate) (OPF), a
water soluble polymer that can be crosslinked to form bio-
degradable and biocompatible hydrogels18. Gelatin micro-
particles (MPs), incorporated into these gels at the time of
crosslinking, have been shown to act as enzymatically di-
gestible porogens to speed in vitro scaffold degradation20.87
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MPs with the desired GF(s) and then encapsulating these
MPs within the OPF network19,20. Alternatively, GFs can
be entrapped within the OPF phase of composites for accel-
erated release19.
Co-encapsulation of bovine chondrocytes with GF-loaded
MPs in these gels has demonstrated the stimulatory action
of incorporated transforming growth factor-b1 (TGF-b1). In
particular, OPF scaffolds co-encapsulating TGF-b1-loaded
MPs and bovine chondrocytes were seen to have statisti-
cally higher cellularity than constructs co-encapsulating
chondrocytes and blank MPs after 21 and 28 days of in vitro
culture21. Most recently, OPF scaffolds were seen to un-
dergo biocompatible degradation and support healthy tis-
sue in-growth in osteochondral defects in 4-month-old,
New Zealand White rabbits18.
The present work employs these OPF scaffolds to inves-
tigate the potential roles of TGF-b1 and insulin-like growth
factor-1 (IGF-1) in osteochondral repair in adult rabbits,
since these GFs are among those most widely investigated
for AC repair2,3. In particular, TGF-b1, a 25 kDa protein, has
been shown to promote the chondrogenic differentiation of
progenitor cells22e24 and to enhance chondrocyte prolifera-
tion21,25,26. IGF-1, a 7.5 kDa protein, appears to primarily
act in an anabolic fashion to increase proteoglycan and
type II collagen synthesis10,27e30. Accordingly, scaffolds
were designed to provide fast, initial release of TGF-b1 as
a chemoattractant and morphogen22,23,31 and/or sustained
release of IGF-1 as a stimulator of extracellular matrix
(ECM) synthesis28,29,32,33. GF loadings were based on con-
centrations shown to be therapeutic in the treatment of full
and partial thickness rabbit and porcine defects17,34.
To investigate the role of TGF-b1 and IGF-1 in cartilage
repair, three different formulations of bilayered OPF hydro-
gels were fabricated and implanted in rabbit osteochondral
defects to spatially localize GF delivery to the approximate
region where cartilage is found in a healthy joint. The ﬁrst
two scaffold formulations (Table I) were loaded with either
TGF-b1 or IGF-1 to separately examine the effects of these
factors on cartilage repair. A third group of scaffolds was
loaded with both TGF-b1 and IGF-1 to examine the combi-
natory role of these molecules. After 12 weeks, tissue repair
in untreated defects and in defects treated by scaffold im-
plantation was examined by histomorphometric analysis.
Additionally, to estimate GF release from these scaffolds,
a 28-day in vitro release study was conducted.
Methods
GELATIN MP LOADING
Using established methods, MPs (50e100 mm) were fab-
ricated from gelatin (Nitta Gelatin Inc., Osaka, Japan),
crosslinked in 40 mM glutaraldehyde (Sigma, St. Louis,
MO), and sterilized by ethylene oxide exposure18,35. Sterile
MPs were then loaded with IGF-1 (R&D Systems,
Table I
In vivo study design
Scaffold GF loading (ng/g gel) Repetitions
TGF-b1 IGF-1
TGF-b1 200 0 11
IGF-1 0 200 10
TGF-b1&IGF-1 200 200 11
No scaffold e e 11Minneapolis, MN) by swelling in an aqueous solution of
IGF-1 (1.19 mg IGF-1/ml phosphate buffered saline (PBS))
to achieve an overall GF loading of approximately 200 ng
IGF-1/g gel in the top crosslinked, layer of scaffolds19. Blank
MPs were loaded with PBS.
OPF SYNTHESIS
High molecular weight poly(ethylene glycol) (PEG) (Poly-
sciences, Warrington, PA) with a number average molecu-
lar weight (Mn) of 25,400 500 and a weight average
molecular weight (Mw) of 41,900 300, was utilized to syn-
thesize OPF (Mn¼ 32,500 1400, Mw¼ 74,900 10,000)
according to previous methods35. The molecular weights
of the parent PEG and resulting OPF were determined by
gel permeation chromatography (n¼ 3)20. OPF was steril-
ized by exposure to UV light for 3 h following an established
technique18.
SCAFFOLD FABRICATION
All implanted scaffolds consisted of two layers: a top, car-
tilage forming layer and a bottom, bone forming layer with
respective thicknesses of 1 and 2 mm. These dimensions
were chosen as a means of restricting GF loading to the up-
per portion of defects, rather than as a model of exact anat-
omy. No GFs or MPs were added to the bone forming layer.
This basic scaffold design was modeled after a design pre-
viously shown to undergo degradation in a timeframe sufﬁ-
cient to support osteochondral tissue repair18.
Approximately 4 h prior to implantation, scaffolds were
fabricated using a 2 step procedure18. To form the bottom
layer, 0.15 g OPF was dissolved in 395 ml of PBS contain-
ing 14 mg N,N 0-methylene bisacrylamide (Sigma) as
a crosslinking agent. Then, 118 ml PBS, 51 ml of 0.3 M tetra-
methylethylenediamine (in PBS) (Sigma) and 51 ml of 0.3 M
ammonium persulfate (in PBS) (Sigma) were added to initi-
ate crosslinking. After vortexing, the suspension was in-
jected into a cylindrical Teﬂon mold to a height of 2 mm
and incubated at 37C for 5 min to achieve partial crosslink-
ing, enabling lamination to a second layer18,35.
During this time, the polymer solution for the top scaffold
layer was prepared as outlined above, except that 32 mg
IGF-1-loaded or PBS-loaded MPs were added. For scaf-
folds loaded with TGF-b1, the PBS addition contained
1.65 ng TGF-b1/ml (R&D Systems). The ﬁnal mixture was
injected into the mold to form the upper scaffold layer and
incubated at 37C for 10 min for complete crosslinking.
All PBS, initiator, and bisacrylamide solutions were steril-
ized prior to use by ﬁltration according to an established
procedure18. The cytocompatibility of this initiating system
has been demonstrated by successful cellular encapsula-
tion of bovine chondrocytes21 in OPF hydrogels during
crosslinking. The ﬁnal dimensions of all scaffolds matched
the dimensions of rabbit osteochondral defects (3 mm in di-
ameter 3 mm in depth)36 with the top, scaffold layer con-
taining 200 ng of the indicated GF(s) per g crosslinked gel
(Table I).
QUANTIFICATION OF IN VITRO GF RELEASE
To approximate the expected in vivo release proﬁles of
TGF-b1 and IGF-1, dual release of these GFs from scaf-
folds was assessed in vitro in standard PBS or PBS con-
taining 370 ng bacterial collagenase 1A (Sigma) per ml.
Since gelatin is degraded primarily by enzymatic hydrolysis,
this collagenase concentration was chosen to model tissue
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with osteoarthritis37. Single layer scaffolds (3 mm in diame-
ter and 1 mm in thickness) were crosslinked as described
above with the exception that one of the two GF solutions
contained a trace amount of I125 labeled-GF (Perkin Elmer
Life Sciences, Boston, MA) to detect drug release. Thus,
two sets of scaffolds were fabricated to separately detect
TGF-b1 and IGF-1 release. Previously, GF release from
these scaffolds has been shown to be controlled by scaffold
composition, rather than protein interactions19. Accordingly,
the individual release of TGF-b1 and IGF-1 from scaffolds
incorporating only one GF was not assessed.
After crosslinking, scaffolds (n¼ 6) were placed in the in-
dicated buffer (3 ml) and were agitated on a shaker table
(70 rpm) at 37C. The supernatant of each specimen was
collected and replaced by fresh buffer following an estab-
lished schedule19,20. GF release was determined by corre-
lation of measured radioactivity (Cobra II Autogamma,
Packard, Meridian, CT) to a standard curve.
ANIMAL SURGERY
Twenty-four, 6-month-old New Zealand White rabbits
were utilized in this study. Adult rabbits were utilized since
the capacity for AC repair decreases with age38. All surgical
procedures were based on an established bilateral, rabbit,
osteochondral defect model18,36 and were approved by
the Animal Care and Use Committees of Radboud Univer-
sity Nijmegen and Rice University. This animal model was
selected for its ease in animal housing (facility cost and
size) while enabling defects to be placed at a biomechani-
cally loaded joint site (medial femoral condyle). Prior to sur-
gery, anesthesia was induced by an intravenous injection of
Hypnorm (0.32 mg/ml fentanyl citrate and 10 mg/ml ﬂuani-
sone) and atropine. General anesthesia was then main-
tained by a mixture of nitrous oxide, isoﬂurane, and
oxygen administered through a ventilator. To minimize
peri-operative infection risk and post-operative discomfort,
antibiotic prophylaxis (Baytril 2.5%, Enroﬂoxacin 5e10 mg/
kg) and Fynadyne was preoperatively administered.
Following anesthesia, rabbits were immobilized on their
back. Both legs were then shaved and disinfected with
povodineeiodine. The left kneewas exposed through amedial
parapatellar longitudinal incision. After lateral luxation of the
patella, the medial femoral condyle was exposed. With the
knee maximally ﬂexed, a full-thickness defect (3 mm in di-
ameter 3 mm in depth) was created in the center of the
condyle using a dental drill (KAVO, Intrasept 905, KAVO
Nederland BV, Vianen, The Netherlands). A 2 mm drill bit
was ﬁrst used to establish a 2 mm diameter defect and
then gradually enlarged using drill bits with diameters of
2.8 and 3.0 mm. All bits were fashioned with stop to ensure
a defect depth of precisely 3 mm. Debris was removed from
the defect with a curette, and the edge cleaned with a scal-
pel blade.
For rabbits belonging to one of the three experimental
groups, an appropriate scaffold was then placed into the de-
fect, while untreated defects remained empty. Subse-
quently, the patella was repositioned, and the capsule and
muscle closed with a continuous 4e0 Vicryl suture. Finally,
the skin was closed with single intracutaneous 4e0 Vicryl
sutures. This procedure was repeated for the right knee
but with this knee receiving a different treatment from that
of the left knee. Thus, each treatment group utilized 12 rab-
bits (n¼ 12). To minimize discomfort, Fynadyne was ad-
ministered for 2 days postoperatively. The animals were
housed in conventional rabbit cages, which allowed forunrestricted weight-bearing activity, and were observed for
signs of pain, infection, and proper activity.
TISSUE PROCESSING
At 12 weeks post-surgery, rabbits were euthanized by in-
travenous administration of Nembutal (pentobarbital). The
tissue surrounding the medial femoral condyle was re-
trieved en bloc, ﬁxed in 10% buffered formalin (pH 7.4) for
1 week, decalciﬁed in 5% formic acid for 14 days, dehy-
drated through graded ethanols, and embedded in parafﬁn.
Using a microtome (Leica RM 2265, Leica Microsystems,
Bannockburn, IL), longitudinal sections of 6 mm in thickness
were taken from the defects’ center and lateral and medial
edges and then stained with Safranin O to identify the gly-
cosaminoglycans (GAGs) of AC with shades of red and light
green as a neutral counter stain.
HISTOMORPHOMETRIC ANALYSIS
Histological sections (n¼ 3) were blindly and indepen-
dently scored by two evaluators (TH and VJ) using a previ-
ously established graded system18. This histological
scoring method was based on the original O’Driscoll sys-
tem39 and examines the extent of neo-tissue in-growth
and implant degradation, as well as detailed evaluations
of the subchondral and chondral regions (Table II). It should
be noted that the scale for thickness of the neo-formed car-
tilage was modiﬁed from its original form18. Previously, neo-
cartilage thickness was scored from 0 to 3, with scores of 3
and 2, respectively, indicating cartilage of ‘‘increased thick-
ness’’ and ‘‘similar thickness’’ to normal AC. However, for
the present study, this scale was revised so that maximum
scores represent the desired healing response for all pa-
rameters. Additionally, the criterion for classifying chondral
tissue morphology was further speciﬁed to clearly distin-
guish between ﬁbrocartilage and ﬁbrous tissue. In particu-
lar, a neo-surface was designated as ‘‘ﬁbrous’’ if less than
75% of its cell population was observed to have a spherical,
chondrocyte-like morphology (Table II).
STATISTICAL ANALYSIS
A signiﬁcance level of 0.05 was utilized for all statistical
analysis. The F test was used for the comparisons of in vitro
TGF-b1 and IGF-1 release values. Following previous
methods, ordered logistic regression of histological scores
was performed using SAS Version 8.2 statistical software
(SAS, Cary, NC, USA) to analyze the potential single factor
effects of treatment group and location within the defect
(edge vs center sections)18,40. Figures display average val-
ues standard deviation (SD) of the measured variable.
Results
IN VITRO GF RELEASE
TGF-b1 and IGF-1 release experiments estimated GF re-
lease kinetics from OPF scaffolds (Fig. 1) in standard PBS
and in collagenase-containing PBS (CC-PBS). The later
buffer was utilized since gelatin MPs degrade primarily by
enzymatic hydrolysis20. High TGF-b1 burst release oc-
curred within the ﬁrst 3 days (65.5 3.3% in PBS and
60.8 3.4% in CC-PBS) as expected for proteins released
from the OPF phase of scaffolds. More speciﬁcally, GFs are
released by diffusion as OPF scaffolds swell, and burst
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Histological scoring system for the overall defect (a), subchondral
region (b), and chondral region (c)
(a) Overall defect evaluation (throughout the entire
defect depth)
Score
1. Percent ﬁlling with neo-formed tissue
100% 3
>50% 2
<50% 1
0% 0
2. Percent degradation of the implant
100% 3
>50% 2
<50% 1
0% 0
(b) Subchondral bone evaluation Score
3. Percent ﬁlling with neo-formed tissue
100% 3
>50% 2
<50% 1
0% 0
4. Subchondral bone morphology
Normal, trabecular bone 4
Trabecular, with some compact bone 3
Compact bone 2
Compact bone and ﬁbrous tissue 1
Only ﬁbrous tissue or no tissue 0
5. Extent of neo-tissue bonding with adjacent bone
Complete on both edges 3
Complete on one edge 2
Partial on both edges 1
Without continuity on either edge 0
(c) Cartilage evaluation Score
6. Morphology of neo-formed surface tissue
Exclusively AC 4
Mainly hyaline cartilage 3
Fibrocartilage (spherical morphology observed
with 75% of cells)
2
Only ﬁbrous tissue (spherical morphology observed
with <75% of cells)
1
No tissue 0
7. Thickness of neo-formed cartilage
Similar to the surrounding cartilage 3
Greater than surrounding cartilage 2
Less than the surrounding cartilage 1
No cartilage 0
8. Joint surface regularity
Smooth, intact surface 3
Surface ﬁssures (<25% neo-surface thickness) 2
Deep ﬁssures (25e99% neo-surface thickness) 1
Complete disruption of the neo-surface 0
9. Chondrocyte clustering
None at all 3
<25% chondrocytes 2
25e100% chondrocytes 1
No chondrocytes present (no cartilage) 0
10. Chondrocyte and GAG content of neo-cartilage
Normal cellularity with normal Safranin O staining 3
Normal cellularity with moderate Safranin O staining 2
Clearly less cells with poor Safranin O staining 1
Few cells with no or little Safranin O staining or no cartilage 0
11. Chondrocyte and GAG content of adjacent cartilage
Normal cellularity with normal GAG content 3
Normal cellularity with moderate GAG content 2
Clearly less cells with poor GAG content 1
Few cells with no or little GAGs or no cartilage 0release is greatly inﬂuenced by hydrogel mesh size19,35.
Lower burst release was expected for IGF-1 since gelatin
MPs were utilized as an intermediate carrier, making drug
release dependent on enzymatic degradation of the gelatin
network and diffusion through the scaffold19,20. Indeed, IGF-
1 burst release was only 28.4 1.4% in PBS and
43.3 4.9% in CC-PBS, statistically lower than the corre-
sponding values for TGF-b1 release. Likewise, 28-day
cumulative IGF-1 release in PBS (47.3 2.0%) and in
CC-PBS (67.4 4.0%) was signiﬁcantly lower than the
corresponding TGF-b1 release values (84.6 1.1% in
PBS and 83.6 1.5% in CC-PBS).
ANIMAL HEALTH AND MACROSCOPIC JOINT APPEARANCE
AT RECOVERY
Animals regained full movement within approximately 1
week with normal behavior and movement observed
throughout the 12-week period. It should be noted that
ﬁve specimens were removed from the study due to compli-
cations common to adult rabbits but unrelated to the surger-
ies (obstructed digestive tract and pre-existing bacterial skin
infection). Accordingly, each treatment group included
10e11 specimens. With these joints, no signs of inﬂamma-
tion, infection, or swelling were noticed upon visible inspec-
tion of the joint surfaces at 12 weeks.
HISTOLOGICAL APPEARANCE
Three histological sections per defect were observed by
light microscopy, allowing for assessment of the healing re-
sponse at the defect edges and center (Figs. 2, 4e7). The
subchondral regions of untreated defects contained a
majority of osseous tissue. However, in eight of 11 defects,
cartilaginous tissue regions occupied up to 30% of the
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Fig. 1. In vitro IGF-1 (C) and TGF-b1 (B) release from OPF scaf-
folds in PBS (a) and in CC-PBS (b). Data are shown as average cu-
mulative release with error bars representing SD (n¼ 6).
191Osteoarthritis and Cartilage Vol. 15, No. 2subchondral region. These regions were generally covered
by a ﬁbrous surface and primarily existed at the subchon-
dral/chondral interface. However, in some cases, this un-
remodeled tissue penetrated as far as 2 mm from the joint
surface. The neo-surface of untreated defects was mainly
composed of ﬁbrous tissue and often extended into the joint
space (Fig. 4). In general, the neo-surface of control spec-
imens was highly disrupted by ﬁssures.
Fig. 2. Histological section displaying ﬁbrocartilage in-growth near
the chondral defect margins and signiﬁcant subchondral restora-
tion. The boxed regions in (a) (2 magniﬁcation) are shown at
20 magniﬁcation to illustrate the spherical shape of cartilage cells
in the neo-surface (b) and small regions of remodeling tissue in
subchondral region (c). This defect was treated by IGF-1 delivery.In all sections of specimens treated with OPF scaffolds,
no remaining hydrogel material or MPs were observed,
and degradation appeared to be complete at 12 weeks
(Figs. 2, 5e7). The subchondral regions of these defects
were generally ﬁlled with a majority of trabecular bone.
However, like untreated defects, regions of hypertrophic
cartilage were also visible at the subchondral/chondral in-
terface in some specimens within each treatment group.
The frequency of these hyaline subchondral regions (num-
ber of defects per treatment) was 45%, 27%, and 18% in
TGF-b1-, TGF-b1&IGF-1-, and IGF-1-treated defects, re-
spectively. Figure 5 shows the most striking example of car-
tilaginous tissue remaining in the subchondral region.
However, it should be noted that in all other defects, these
regions were conﬁned to less than 30% of the subchondral
zone. In fact, complete subchondral restoration with trabec-
ular bone and complete integration with the surrounding os-
seous tissue were frequently observed (Fig. 7).
The neo-formed surface morphology of defects treated
with scaffolds was primarily composed of ﬁbrous tissue of
variable thickness, but ﬁbrocartilage was observed in sev-
eral specimens within each group. Intense Safranin O stain-
ing and zonal organization of chondrocytes, indicative of
true AC, were rarely observed. However, regions of carti-
lage-like cells were often visible near the defect margins
(Fig. 2), but true AC repair with a zonal organization of cells
was only observed in one defect (an IGF-1-treated defect).
Very thin ﬁbrous tissue was sometimes observed with all
experiment treatments and tended to accompany complete
or near complete subchondral restoration, as exempliﬁed by
Figs. 2 and 7. In other specimens, thick surface tissue with
ﬁssures was observed, especially when subchondral re-
modeling was incomplete (Fig. 6).
HISTOMORPHOMETRIC ANALYSIS
Quantitative scoring of 11 markers of osteochondral re-
pair (Table II)18 examined the potential effects of GF deliv-
ery and location within the defect (edge vs center). Section
location within the former defect did not signiﬁcantly impact
any of the 11 markers of osteochondral repair, indicating
that the observed tissue response was generally uniform
throughout the defect. However, it should be noted that
regions of un-remodeled subchondral tissue were often
located toward the middle of the subchondral zone on
lateral, medial, and center sections. New bone and chon-
drocytes appeared to inﬁltrate the subchondral and chondral
regions from the defect margins.
No signiﬁcant differences in overall tissue ﬁlling and im-
plant degradation were observed among the four treatment
groups [Fig. 3(a)]. All sections received maximal scores for
scaffold degradation, and scores for overall tissue ﬁlling ap-
proached but did not equal the maximal score. This differ-
ence was due to the very thin neo-surface tissue often
observed amongst specimens from all treatment groups.
Likewise, average scores for bone ﬁlling and bone mor-
phology were below their maximal scores [Fig. 3(b)] since
un-remodeled regions were observed in all treatment
groups. However, the high average scores for bone integra-
tion reﬂect the complete integration commonly observed
with all treatments. Although the frequency of inadequate
bone ﬁlling was highest amongst untreated defects, scaffold
implantation was not observed to signiﬁcantly inﬂuence
subchondral bone repair. However, improved bone healing
with scaffold implantation was not expected since growth
delivery was conﬁned to the upper portion of osteochondral
defects, and repeated research has demonstrated that
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Fig. 3. Comparison of results following histomorphometric analysis of the overall defect (a), subchondral region (b), and chondral region (c).
Data are shown as average scores with error bars representing SD (n¼ 10e11 defects per treatment). Scores with signiﬁcant differences
(P< 0.05) compared to untreated defects (control), defects treated by TGF-b1-loaded scaffolds, and defects treated by dual TGF-b1&IGF-1-
loaded scaffolds are, respectively, indicated by C, T, and D. Untreated control, ,; TGF-b1-delivery, D; TGF-b1&IGF-1 delivery, -; IGF-1
delivery, E.scaffolds alone often serve as insufﬁcient templates to
guide tissue regeneration41e46. Since the goal of this study
was to examine the GF interactions in cartilage repair, GFs
were not delivered to the subchondral bone.As shown in Fig. 3(c), defects treated by IGF-1 delivery
had signiﬁcantly higher scores for six indicators of neo-sur-
face repair when compared to untreated defects. Addition-
ally, IGF-1 delivery resulted in higher scores for ﬁve of the
193Osteoarthritis and Cartilage Vol. 15, No. 2six markers of neo-surface repair (surface morphology, car-
tilage thickness, surface regularity, chondrocyte clustering,
and the GAG and cell content of the neo-surface) when
compared to TGF-b1 delivery. However, when compared
to untreated defects, TGF-b1 delivery, as well as TGF-
b1&IGF-1 co-delivery, only improved scores for the GAG
and cell content of the cartilage surrounding the defect.
These results suggest the potential of IGF-1 delivery
Fig. 4. Histological section displaying the thick ﬁbrous tissue com-
monly observed at the neo-surface and that often accompanied un-
remodeled cartilaginous regions in the subchondral zone. The boxed
regions in (a) (2 magniﬁcation) are shown at 20 magniﬁcation to
illustrate the cell morphology observed in portions of the chondral
(b) and subchondral (c) regions. This defect was untreated.strategies in chondral repair. However, since a large varia-
tion in tissue quality was observed within this treatment
group, these ﬁndings should be interpreted cautiously.
True AC with a zonal arrangement of chondrocytes was
only observed in one IGF-1 treated defect, leading to higher
average scores and SDs for this treatment group. As re-
ﬂected by the average scores in Fig. 3(c), ﬁbrous tissue
was generally observed in the neo-surface of all treatments.
Fig. 5. Histological section displaying the most striking example of
cartilaginous tissue remaining in the subchondral defect area. The
boxed regions in (a) (2 magniﬁcation) are shown at 20 magniﬁ-
cation to illustrate the ﬁbrous tissue and hypertrophic cartilage ob-
served in portions of the chondral (b) and subchondral (c) regions,
respectively. This defect was treated by IGF-1 delivery.
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1-treated defects, and 20% of untreated defects, had
sufﬁcient ‘‘cartilage-like’’ cells to meet the criterion for the
classiﬁcation as non-ﬁbrous [Table II(c)].
One of the most interesting ﬁndings of this study cen-
tered upon the apparent lack of TGF-b1 and IGF-1 synergy
when simultaneously delivered to osteochondral defects.
Compared to untreated defects, treatment with both GFs
Fig. 6. Histological section displaying excessive ﬁbrous tissue
growth into the joint space and signiﬁcant subchondral restoration.
The boxed regions in (a) (2magniﬁcation) are shown at 20mag-
niﬁcation to illustrate the spindle-like cells in the neo-surface (b) and
small regions of remodeling tissue in subchondral region (c). This
defect was treated by TGF-b1 delivery.only improved scores for only two parameters: the regularity
of the neo-surface and the chondrocyte/GAG content of
the adjacent surface. However, it should again be noted,
that these GFs were delivered with different release kinet-
ics. While IGF-1 was expected to be delivered through-
out the ﬁrst several weeks of healing, TGF-b1 was
expected to be delivered to the wound site within the ﬁrst
few days.
Fig. 7. Histological section displaying thin ﬁbrous tissue growth
along the surface of a joint with complete subchondral restoration.
The boxed regions in (a) (2magniﬁcation) are shown at 20mag-
niﬁcation to illustrate the morphology of the ﬁbrous neo-surface (b)
and the mature bone in the subchondral region (c). This defect was
treated by TGF-b1&IGF-1 delivery.
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Numerous scaffolds have been investigated for cartilage
drug delivery2, but as of yet, these scaffolds have not been
employed to examine the in vivo effects of multiple GFs.
OPF scaffolds have numerous material parameters which
can be manipulated to achieve desired drug release
rates19,20,35 and to study delivery of multiple GFs. Here,
we examine in vivo delivery of two proteins, TGF-b1 and
IGF-1, whose single and combined effects have been the
focus of numerous in vitro investigations.
TGF-b1 has been shown to promote in vitro chondro-
genic differentiation of mesenchymal stem cells and chon-
drocyte proliferation21e24,47,48. However, stimulation of
GAG synthesis and mRNA expression for type II collagen,
important markers of the chondrogenic phenotype, fre-
quently do not accompany TGF-b1-stimulated prolifera-
tion5,12,21. However, several studies have demonstrated
that together TGF-b1 and IGF-1 can synergistically pro-
mote proliferation, GAG synthesis, and collagen II expres-
sion in vitro6,8,9,12. These results are not surprising since
IGF-1 was initially identiﬁed for its ability to promote GAG
incorporation into proteoglycans and has been shown to
regulate cartilage matrix synthesis27,28,33. Due to these re-
ports, scaffolds for in vivo analysis of possible TGF-b1/IGF-1
synergy were designed to provide fast, initial release of
TGF-b1 (Fig. 1) as a morphogen in the earlier stages of
healing22,23 and sustained release of IGF-1 as a progres-
sion factor28,29,32,33.
Surprisingly, when these scaffolds were used in the repair
of osteochondral defects in adult rabbits, combinatory deliv-
ery of TGF-b1 and IGF-1 did not result in widespread im-
provement to the quality of the neo-surface when
compared to untreated defects. Dual delivery of TGF-b1
and IGF-1 only appeared to improve neo-surface regularity
(vs untreated defects), indicating that ﬁndings of in vitro
TGF-b1 and IGF-1 synergy do not directly correlate with
in vivo observations. These inconsistencies may be due
to the complex in vivo environment and the numerous cell
types involved in the healing response. For example, previ-
ous studies have demonstrated TGF-b1’s pluripotent stimu-
lation of chemotaxis and proliferation of inﬂammatory cells,
ﬁbroblasts, chondrocytes, and other cells31,34,49,50.
The stimulatory activity of TGF-b1 incorporated into OPF
hydrogels has previously been demonstrated in vitro.
Speciﬁcally, co-encapsulation of TGF-b1-loaded MPs and
bovine chondrocytes within OPF hydrogels was seen to
stimulate in vitro cell proliferation when compared to chon-
drocytes co-encapsulated with unloaded MPs21. The pres-
ent study again utilized OPF-gelatin MP networks to
deliver TGF-b1 in vivo, but TGF-b1 was not seen to improve
in vivo repair. These ﬁndings again suggest the drastically
different in vivo and in vitro environments. However, since
the TGF-b1 release kinetics in the present in vivo study
and aforementioned in vitro study were slightly different, re-
sults cannot be directly compared. In the present study, ap-
proximately 60% of the TGF-b1 was expected to be
delivered to the surrounding tissue within 72 h post-surgery,
while more sustained release of TGF-b1 was expected in
the in vitro study.
Furthermore, it should be noted differences in animal
models may also give rise to vastly different cellular envi-
ronments. The TGF-b1 dose utilized in the present study
(200 ng/g crosslinked gel) was previously reported to stim-
ulate cell recruitment to porcine and rabbit chondral de-
fects17,31. Additionally, a similar TGF-b1 concentration
(600 ng/ml) was reported to stimulate partial cartilage repairwhen utilized in combination with an antiangiogenic factor in
full-thickness porcine defects34. While these reports were
utilized as a starting point for determining GF doses in the
current model, differences in the animal species, defect di-
mension and location (patellar groove vs femoral condyle),
and scaffold material properties may lead to vastly different
healing situations.
Since high dosages of exogenous TGF-b151e54 have fre-
quently been associated with in vivo formation of osseous
or chondroid outgrowths in joints, increases in the amount
of TGF-b1 delivered in vivo should be avoided. In the pres-
ent study, numerous instances of excessive tissue growth
at the neo-surface were observed in defects treated by
TGF-b1 and TGF-b1&IGF-1 delivery, as well as in untreated
defects. Accordingly, IGF-1 may be a more promising can-
didate than TGF-b1 for delivery strategies, especially since
this GF appears to act primarily as a progression factor33.
Here, individual delivery of IGF-1 resulted in consistently
higher scores than untreated defects and defects treated
with only TGF-b1 [Fig. 3(c)]. However, given the large var-
iation in healing responses in IGF-1-treated defects, these
results do not conclusively conﬁrm the therapeutic ability
of this GF. Instead, these results and the apparent lack of
TGF-b1&IGF-1 synergy demonstrate the necessity for
in vivo studies to more accurately examine the role of
GFs in healing. This study assessed the effects of rapid
TGF-b1 and/or sustained IGF-1 delivery to osteochondral
defects. Future work should entail a more detailed examina-
tion of the effects of various TGF-b1 and IGF-1 release
kinetics upon healing.
Additionally, the present study’s thorough histological
analysis led to several other interesting observations. Our
ﬁndings of hyaline cartilaginous regions in the subchondral
zone agree with previous reports55 and the suggestion that
the post-injury response involves a rapid inﬂux of mesen-
chymal cells into the defect area and the fabrication of em-
bryonic-like cartilage tissue throughout the defect (Fig. 5)
and sometimes into the joint space55,56. As shown in
Fig. 4, this cartilage appears to become hypertrophic in
the subchondral zone as bone formation is initiated at the
defect margins and progressively inward. These observa-
tions support previous suggestions that vascularization, re-
sulting in bone formation, controls the rate at which the
cartilaginous tissue disappears56. However, the cartilage
repair tissue near the chondral surface, initially isolated
from vascularization, appears to undergo a simultaneous,
but separate remodeling as illustrated by the ﬁbrous tissue
along the neo-surface in Figs. 4e6. Since spherical chon-
drocyte-like cells and GAG staining were primarily ob-
served near the chondral defect margins (Fig. 2), cells
near the joint surface appear to play a major role in this
process17,31.
Understanding the role of GF interactions in chondro-
genesis will undoubtedly prove beneﬁcial, since very thin
surface tissue commonly accompanied complete sub-
chondral restoration in this study (Fig. 6) and in other inves-
tigations55,57. GF delivery via scaffolds remains a logical
strategy for AC repair, but this study highlights the need
for the caution when interpreting the implications of in vitro
studies. As evident by this research, the in vitro effects of
GFs, including the synergistic actions of multiple factors,
may not always translate to the wound healing environ-
ment. Thus, thorough in vivo analysis of GF interactions
in tissue repair is necessary. The ﬂexible design properties
of OPF hydrogels allow these scaffolds to be used as pow-
erful tools to explore the effectiveness of various GF deliv-
ery regimes in the cartilage wound healing environment
196 T. A. Holland et al.: In vivo growth factor deliveryand in many other tissue defects. Accordingly, these sys-
tems will help scientists to unravel the vital interactions
and signaling cascades of these complex molecules in
tissue repair.
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